Ticker

Analyst Price Targets — AVTX

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
August 7, 2026 11:42 amGuggenheim$48.00$18.70TheFly Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim
August 7, 2026 10:13 amH.C. Wainwright$30.00$18.70TheFly Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright
July 6, 2026 3:07 pmLeerink Partners$38.00$19.80TheFly Avalo Therapeutics initiated with an Outperform at Leerink
May 14, 2026 11:58 amWedbush$34.00$19.46TheFly Avalo Therapeutics price target lowered to $34 from $40 at Wedbush
May 14, 2026 11:15 amMizuho Securities$45.00$19.85TheFly Avalo Therapeutics price target raised to $45 from $39 at Mizuho
May 14, 2026 10:12 amH.C. Wainwright$35.00$19.85TheFly Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
May 11, 2026 10:51 amPiper Sandler$60.00$21.57TheFly Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler
May 6, 2026 11:21 amBTIG$58.00$16.26TheFly Avalo Therapeutics price target raised to $58 from $40 at BTIG
April 8, 2026 8:38 pmWolfe Research$48.00$14.41TheFly Avalo Therapeutics initiated with an Outperform at Wolfe Research
February 2, 2026 11:10 amGuggenheim$50.00$15.11TheFly Avalo Therapeutics initiated with a Buy at Guggenheim

Latest News for AVTX

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on…

GlobeNewsWire • Jul 22, 2026
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

WAYNE, Pa. , July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

Globe News Wire • Jul 7, 2026
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

GlobeNewsWire • Jul 7, 2026
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26,…

GlobeNewsWire • Jun 26, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for AVTX.

No House trades found for AVTX.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top